Restore Vision

• Repurposing and Innovation: The consortium is evaluating six existing drugs already approved for other conditions and developing three new compounds, leveraging their potential for vision restoration in rare ocular surface diseases.
• Disease Models: Advanced laboratory and preclinical models are used to validate therapeutic targets, test drug efficacy, and understand disease mechanisms in detail.
• Formulation Science: The team is optimizing safe and effective drug formulations for use as eye drops or subconjunctival injections.
• Clinical Translation: Promising candidates will move into phase 1b and compassionate clinical trials to assess safety and initial effectiveness in patients.
• Data Management: The MeDIC team at University Hospital Cologne is responsible for preparing and updating the Data Management Plan, ensuring compliance with data protection and open science standards.

• Project Management & Coordination: Ensuring smooth execution and timely reporting across all work packages.
• Validation of Drug Targets: Testing the effects of candidate drugs on human tissues and fluids to understand their mechanisms of action.
• Formulation Development: Creating eye drop and injectable versions of promising compounds.
• Preclinical Studies: Using disease models to evaluate safety and efficacy.
• Clinical Trials: Conducting first-in-human studies for the most promising therapies.
• Data Management: Delivering and updating the Data Management Plan and reporting on data collection strategies.

Restore Vision unites 10 partners from 9 EU countries, including leading research institutions, SMEs, and a European patient organisation. The combined expertise covers basic science, clinical research, pharmaceutical development, project management, and patient advocacy.